# This Study Will Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of MET097 in Adult Participants With Overweight or Obesity

> **NCT06857617** · PHASE1,PHASE2 · COMPLETED · sponsor: **Metsera, a wholly owned subsidiary of Pfizer** · enrollment: 120 (actual)

## Conditions studied

- Obesity and Overweight

## Interventions

- **BIOLOGICAL:** (Part C) MET097
- **BIOLOGICAL:** (Part C) Placebo

## Key facts

- **NCT ID:** NCT06857617
- **Lead sponsor:** Metsera, a wholly owned subsidiary of Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-04-01
- **Primary completion:** 2025-01-03
- **Final completion:** 2025-03-15
- **Target enrollment:** 120 (ACTUAL)
- **Last updated:** 2026-01-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06857617

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06857617, "This Study Will Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of MET097 in Adult Participants With Overweight or Obesity". Retrieved via AI Analytics 2026-08-01 from https://api.ai-analytics.org/clinical/NCT06857617. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*